计算溶液所需的质量、体积或浓度。
为什么选择此级别
提供 ≥98% 纯度，适用于对基线干扰要求严格的色谱和分析工作流程。
储存与运输
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
质量文档
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
文献证明
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
概述
BRD4/CK2-IN-1 is the first highly effective and oral active dual-target inhibitor of BRD4/CK2 (bromodomain-containing protein 4/casein kinase 2), with IC 50 s of 180 nM and 230 nM for BRD4 and CK2 , respectively. BRD4/CK2-IN-1 has strong anticancer activity without obvious toxicities. BRD4/CK2-IN-1 induces apoptosis and autophagy -associated cell death in triple-negative breast cancer (TNBC)
In Vitro
BRD4/CK2-IN-1 (compound 44e) (0-25 μM; 24 hours) has anti-proliferation effect with IC 50 s of 2.66 and 3.52 μM in MDA-MB-231 and MDA-MB-468 cells, respectively. BRD4/CK2-IN-1 (0-10 μM; 24 hours) dose-dependently induces apoptosis of MDA-MB-231 and MDA-MB-468 cells. BRD4/CK2-IN-1 (0-10 μM; 24 hours) dose-dependently downregulates Bcl-2 but upregulates Bax and cleaved caspase-3. BRD4/CK2-IN-1 (0-10 μM; 24 hours) significantly downregulates the autophagy substrate p62 and up-regulated beclin-1 and LC3II in MDA-MB-231 and MDA-MB. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: MDA-MB-231, MDA-MB-468 cells Concentration: 0, 0.19, 0.39, 0.78, 1.56, 3.13, 6.25, 12.5, 25 μM Incubation Time: 24 hours Result: Showed anti-proliferative rates in MDA-MB-231 and MDA-MB-468 cells (IC 50 = 2.66 and 3.52 μM, respectively). Apoptosis AnalysisCell Line: MDA-MB-231, MDA-MB-468 cells Concentration: 0, 2.5, 5, 10 μM Incubation Time: 24 hours Result: Dose-dependently induced apoptosis of MDA-MB-231 and MDA-MB-468 cells. Western Blot AnalysisCell Line: MDA-MB-231, MDA-MB-468 cells Concentration: 0, 2.5, 5, 10 μM Incubation Time: 24 hours Result: Dose-dependently downregulated Bcl-2 but upregulated Bax and cleaved caspase-3. Cell Line: Concentration: Incubation Time: Result:
In Vivo
BRD4/CK2-IN-1 (25 and 50 mg/kg; intragastric administration; daily for 19 days) inhibits tumor growth in TNBC xenograft models . BRD4/CK2-IN-1 (25 and 50mg/kg; intragastric administration; daily for 19 days) shows weak toxicity measured by body weight loss in the MDA-MB-231 and MDA-MB-468 xenograft models . Preliminary Assessment of Pharmacokinetics (PK) profile of BRD4/CK2-IN-1 . Parameter iv (1 mg/kg) po (10 mg/kg) T 1/2 (h) 4.21±0.57 5.14±0.71 C max (ng/mL) 237±11 206±6 AUC 0- t (ng·h/mL) 579±49 2079±130 AUC 0-∞ (ng·h/mL) 588±36 2090±146 V Z (L/kg) 21.1±2.6 CL ((mL/min)/kg) 57.4±1.3 F (%) 32.5 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female nude mice (BALB/c, 6-8 weeks, 20-22 g) bearing MDA-MB-231 cells Dosage: 25 and 50 mg/kg Administration: Intragastric administration; daily for 19 days Result: Had the most pronounced tumor growth inhibition (TGI) (63.8%) in the MDA-MB-231 xenograft tumor model at 50 mg/kg.
Form:Solid
IC50& Target:BRD4 180 nM (IC 50 ) CK2 230 nM (IC 50 )
规格
别名
BRD4/CK2-合一
规格或纯度
≥98%
英文名称
BRD4/CK2-IN-1
生化机理
BRD4/CK2-IN-1 是首个高效口服活性 BRD4/CK2（含溴多聚酶链蛋白 4/酪蛋白激酶 2）双靶点抑制剂，对 BRD4 和 CK2 的 IC 50 s 分别为 180 nM 和 230 nM。BRD4/CK2-IN-1 具有很强的抗癌活性。
储存条件
-20°C储存
运输条件
超低温运输
作用类型
抑制剂
纯度
≥98%
名称和识别符
分子类型
小分子
分子量
564.03
技术文档
高级数据
化学和物理性质
溶解性
DMSO : 20 mg/mL (35.46 mM; ultrasonic and warming and adjust pH to 3 with HCl and heat to 60°C)
质检证书（CoA,COO,BSE/TSE 和分析图谱)
C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:
溶液计算器
产品仅提供给经过验证的企业、机构和合格的专业人员用于研发。不适用于人类、动物、诊断或治疗。
Copyright © 2023至今 上海阿拉丁生化科技股份有限公司 保留所有权利。
危险品化学品经营许可证（带存储）